Test Diagnostics Systems News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CALGARY, AB, May 10, 2021 /PRNewswire/ -  FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary "FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces the next phase of its ongoing clinical trials with its trial partner Toolbox Medical Innovations ("Toolbox"). The Company is pleased to report that approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals, are being identified from six clinical site locations across Califor...

"FluroTest" or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces it has signed a strategic  Memorandum of Understanding ("MOU") with TTS"), one of North America's premier providers of health testing to the professional sports, entertainment, venue ticketing and travel industries. Under the terms of the non-binding MOU, FluroTest and TTS will launch and pilot a first-of-its-kind, high-volume Covid-19 testing system from one of the LA-based screening facilities, with the intent to transition from research-use...